Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

F3254

Sigma-Aldrich

Fibrinopeptide A human

≥96% (HPLC)

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C63H97N19O26
Číslo CAS:
Molekulová hmotnost:
1536.56
MDL number:
UNSPSC Code:
12352202
PubChem Substance ID:
NACRES:
NA.77

biological source

human

Quality Level

assay

≥96% (HPLC)

form

powder

technique(s)

ELISA: suitable
mass spectrometry (MS): suitable

UniProt accession no.

storage temp.

−20°C

SMILES string

CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(O)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(O)=O)NC(=O)C(C)N)C(=O)NC(C)C(=O)NC(CCC(O)=O)C(=O)NCC(=O)NCC(=O)NCC(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(O)=O

InChI

1S/C63H97N19O26/c1-29(2)19-37(57(102)73-32(6)53(98)76-35(15-17-48(91)92)55(100)70-24-43(85)68-23-42(84)69-25-46(88)82-51(30(3)4)61(106)77-36(62(107)108)13-10-18-67-63(65)66)79-58(103)38(20-33-11-8-7-9-12-33)80-59(104)39(21-49(93)94)75-45(87)27-71-54(99)34(14-16-47(89)90)74-44(86)26-72-56(101)41(28-83)81-60(105)40(22-50(95)96)78-52(97)31(5)64/h7-9,11-12,29-32,34-41,51,83H,10,13-28,64H2,1-6H3,(H,68,85)(H,69,84)(H,70,100)(H,71,99)(H,72,101)(H,73,102)(H,74,86)(H,75,87)(H,76,98)(H,77,106)(H,78,97)(H,79,103)(H,80,104)(H,81,105)(H,82,88)(H,89,90)(H,91,92)(H,93,94)(H,95,96)(H,107,108)(H4,65,66,67)

InChI key

JWICNZAGYSIBAR-UHFFFAOYSA-N

Gene Information

human ... FGA(2243)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Amino Acid Sequence

Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg

General description

Fibrinopeptide A (FPA) is produced from the N-terminal Aα region of fibrinogen protein, on cleavage by thrombin. It is composed of 16 amino acids.

Application

Fibrinopeptide A human has been used for protein control experiments performed during sandwich ELISA microarray assay to distinguish between plasma and serum fibrinogen samples. It has also been used in a peptide mixture along with BSA (bovine serum albumin) to ascertain the relation between fragmentation voltage and peptide ion drift time for IMS-MS (ion mobility spectrometry coupled with mass spectrometry).

Biochem/physiol Actions

Fibrinogen plays essential roles in coagulation of blood, wound healing, platelet aggregation and has roles in various other physiological processes. Increase in the levels of fibrinopeptide A (FPA) is found in multiple disorders such as coronary artery disease, disseminated intravascular coagulation, arterial thrombosis, deep venous thrombosis and cancers.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

H L Nossel et al.
The Journal of clinical investigation, 54(1), 43-53 (1974-07-01)
Since thrombin cleaves fibrinopeptides A (FPA) and B from the NH(2)-terminal end of the fibrinogen molecule, measurement of fibrinopeptide levels in plasma may provide a direct index of thrombin action. Recently a radioimmunoassay for FPA has been developed, and in
Xi Chen et al.
Environmental toxicology and pharmacology, 33(2), 191-196 (2012-01-10)
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitously distributed endocrine disruptors. To investigate peptide changes in the sera of rats chronically exposed to TCDD and to explore the association of these changes with liver morphology, TCDD was administrated to male rats at doses
Giancarlo Agnelli et al.
The New England journal of medicine, 366(7), 601-609 (2012-02-18)
Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism. Limited data support the clinical benefit of antithrombotic prophylaxis. In this double-blind, multicenter trial, we evaluated the efficacy and safety of the ultra-low-molecular-weight heparin semuloparin for prevention of
Thromboprophylaxis in patients receiving chemotherapy.
Claude Bachmeyer et al.
The New England journal of medicine, 366(19), 1839-1839 (2012-05-11)
Routine heparin for patients with cancer? One answer, more questions.
Elie A Akl et al.
The New England journal of medicine, 366(7), 661-662 (2012-02-18)

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.